Become A Featured Company

GB Sciences and NRC Research Institute Apply Crowdsourcing and Big Data Analytics to the Discovery and Validation

Ryan Allway

November 10th, 2014

News, Top News

[stockchart symbol=GBLX]

GrowBLOX Sciences, Inc., “GB Sciences” [stockquote symbol=GBLX], a company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize safe and consistent medicinal cannabis, and NRC Research Institute (“NRC”) announce the joint development of a crowdsourcing application to discover cannabis-based therapeutic combinations that are effective in the treatment of serious disorders. The app uses real-time patient feedback, impairment testing, and biometric measurements to assess the efficacy of therapeutic products made with prescreened cannabis strains.

“Patients need help in finding the correct strain of Cannabis to treat their medical conditions,” said Andrea L. Small-Howard, PhD, MBA, Chief Science Officer of GB Sciences. “Because GB Sciences has a suite of proprietary GrowBLOXTM technologies designed to produce consistent, medical-grade cannabis products with known cannabinoid-terpene profiles, we will soon be able to correlate patient symptoms and pathology with the right ‘cocktails’ of active ingredients for the first time. Any trial that has tested cannabis-based products without controlling the levels of active ingredients in the plant strains cannot accurately gauge their medicinal value. Once cannabis cocktail mixtures are validated as effective, they will become the source of our novel cannabinoid therapies. The app is our Drug Discovery Engine.”

The research firms anticipate thousands of patients will download and use their free electronic Patient Reported Outcomes (GBLX-PRO) app to report and track their experience with different pre-screened strains of medicinal cannabis that are provisionally assigned to seven different treatment categories. In addition, the anonymously collected patient data will contribute to cannabis research and enable GB Sciences to demonstrate which of its pre-screened strains are effective in treating medical conditions such as Parkinson’s disease, epilepsy, anxiety, insomnia, pain and metabolic disorders. The GBLX-PRO app will aid in creating personalized treatments for patients with unmet clinical needs.

“This exciting strategic partnership with GB Sciences provides for the successful development of their product pipeline and will help innovate measurements for high-priority therapeutic indications in the cannabis drug development process,” said Tony Ortiz, Ph.D., CEO of NRC Research Institute.

Collection and analysis of the two sets of data—cannabis strain potency and patient response to therapy—will enable GB Sciences to monitor and validate dosage levels and their effectiveness in treating specific medical conditions. The GBLX-PRO app will allow for three levels of participation: 1) self-reporting of clinical results using validated surveys; 2) participation in objective impairment testing; and 3) the collection of biometric data voluntarily submitted by participating patients via smartphone accessories. The GBLX-PRO app collects and combines rich objective and subjective patient feedback with lot-specific growth data that GB Sciences collects from its cannabis-growing operations.

“Crowdsourcing efficacy data is now possible because 23 states and Washington, D.C. allow patients to use cannabis,” said Craig Ellins, CEO of GrowBLOX Sciences. “When collected and properly analyzed in our big data program, the patient information will provide a roadmap pointing which direction we need to head to treat specific illnesses. For the first time, we are going to have the ability to validate our strains for specific disorders.”

To learn more about GB Sciences, Inc., go to www.gbsciences.com.

About GrowBLOX Sciences, Inc.

GB Sciences is a biopharmaceutical research and development company that merges state-of-the-art technologies in plant biology, cultivation technology and post-production processes in order to optimize our safe and consistent medicinal cannabis. The company is pioneering technology, industry-leading processes, and a big data-driven clinical research and development algorithm to bring relief to patients in communities across the country.

About NRC Research Institute

NRC Research is a Clinical Research and Development company with a focus on Contract Research Organization services to the pharmaceuticals and biotechnology companies. NRC Research Institute has worked with numerous globally recognized pharmaceutical and biotechnology companies on the development of experimental medications for FDA approval and other clinical development services.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading